HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hemodynamic, pharmacokinetic and clinical response to CI-930 in congestive heart failure due to ischemic or dilated cardiomyopathy.

Abstract
CI-930, a new type III phosphodiesterase inhibitor, was evaluated for treatment of refractory congestive heart failure. The hemodynamic, pharmacokinetic and clinical response to the drug was determined in 10 patients. At the peak plasma concentration after intravenous CI-930, cardiac index increased from 2.0 to 2.7 liters/min/m2 (p less than 0.002), pulmonary artery wedge pressure decreased from 26 to 17 mm Hg (p less than 0.001) and systemic vascular resistance decreased from 1,999 to 1,471 dynes cm-5 (p less than 0.05). Heart rate and blood pressure did not change significantly. Similar changes were observed with oral CI-930. Peak CI-930 plasma concentration occurred 1.2 +/- 0.8 hours after oral administration. Beneficial hemodynamic effects were sustained 12 to 18 hours after the oral dose. The sustained hemodynamic effects observed after oral administration appear to be related to an active metabolite of CI-930 that has prolonged duration of action and slow washout. The drug was well tolerated and has potential for treatment of congestive heart failure.
AuthorsS M Jafri, B S Burlew, A D Goldberg, S Olson, J W Froelich, S Goldstein
JournalThe American journal of cardiology (Am J Cardiol) Vol. 59 Issue 12 Pg. 1126-30 (May 01 1987) ISSN: 0002-9149 [Print] United States
PMID3578054 (Publication Type: Journal Article)
Chemical References
  • Phosphodiesterase Inhibitors
  • Pyridazines
  • 4,5-dihydro-6-(4-(imidazol-1-yl)phenyl)-5-methyl-3(2H)-pyridazinone
Topics
  • Administration, Oral
  • Aged
  • Animals
  • Cardiomyopathy, Dilated (complications)
  • Cricetinae
  • Female
  • Heart Failure (drug therapy, etiology)
  • Hemodynamics (drug effects)
  • Humans
  • Kinetics
  • Male
  • Middle Aged
  • Phosphodiesterase Inhibitors (therapeutic use)
  • Pyridazines (administration & dosage, metabolism, therapeutic use)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: